Latest filing published 10 Jun 2026 for Emergent BioSolutions Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Coleen Glessner in Emergent BioSolutions Inc., where the filings describe the role as senior executive. In total, 19 filings cover trades dated from 8 April 2022 to 8 June 2026.
Sales make up the whole of the open-market record (1 sale, €263k). Outside the open market, there are 16 share grants.
The latest filing, published on 10 June 2026, reports a share grant in Emergent BioSolutions Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations